<p>Alto Neuroscience Inc. announced the publication of a review article in the American Journal of Psychiatry, co-authored by members of its leadership team and board. The review consolidates clinical and translational evidence showing that disrupted neuroplasticity is a core biological driver across major psychiatric disorders such as depression, schizophrenia, PTSD, and addiction. The authors highlight the importance of developing translatable biomarkers for neuroplasticity changes in humans, a gap that Alto aims to address with its Precision Psychiatry Platform. The review supports Alto’s strategy of pairing therapies with objective, circuit-level biomarkers and emphasizes the potential of targeting neuroplasticity as a measurable and druggable mechanism for improving psychiatric treatments. These results have already been published and are available online. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

Reuters

iShares Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Alto Neuroscience

VG Health

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

Alto Neuroscience Identifies Neuroplasticity as Key Driver in Psychiatric Disease and Treatment